Scientists at the International Agency for Research on Cancer (IARC) have identified distinct circulating metabolites linked to triple-negative breast cancer risk, separating them from pathways tied to hormone receptor-positive tumors. Published on August 11, 2026, in BMC Medicine, the new study applies untargeted metabolomics to uncover biological mechanisms that could eventually explain why certain aggressive cancers develop.
Metabolic Pathways Distinguish Breast Cancer Subtypes
Triple-negative breast cancer accounts for 10% to 15% of newly diagnosed breast cancer cases. It remains one of the most aggressive forms of the disease, carrying limited therapeutic options, high metastatic potential, and poorer overall prognosis compared to other types. Its underlying biology has long remained poorly understood.
To investigate these distinct pathways, researchers used data from a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The analysis included 271 triple-negative breast cancer cases matched with 271 controls, alongside 271 estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) cases matched with 271 controls. Scientists at IARC analyzed plasma samples using an untargeted ultrahigh-performance liquid chromatography-mass spectrometry method that measured more than 3,000 molecular features.
Specific Metabolites Linked to Tumor Risk
The plasma metabolomics analysis revealed clear differences in metabolite associations between tumor subtypes. Higher levels of tyrosine showed an association with a lower risk of developing triple-negative breast cancer.
In contrast, the study found that elevated levels of uric acid, octenoylcarnitine, hexadecenoylcarnitine, a bilirubin photodegradation product, and 2-hydroxy-3-methylbutyric acid correlated with an increased risk of ER+ and PR+ tumors. Conversely, higher levels of caffeine and 2-furoylglycine were associated with a lower risk of those hormone receptor-positive tumors.
For triple-negative breast cancer specifically, researchers identified 15 unknown metabolites that appeared suggestively specific to the disease’s risk and linked closely to inflammation pathways. These findings suggest that distinct metabolic processes drive different forms of breast cancer.
Implications for Future Research and Prevention
The IARC findings point to metabolic differences that distinguish triple-negative breast cancer development from ER+ or PR+ tumors. While these results offer new insights into underlying biological pathways, researchers emphasize that independent replication is necessary.
Confirming these metabolite associations in future prospective studies could enhance understanding of triple-negative breast cancer etiology. Such insights may eventually highlight lifestyle determinants or biological processes that influence disease development, though additional clinical research is required before these markers can guide preventive strategies.